Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Azitra Inc.

  • Richard Andrews , Azitra, Inc.

Azitra Inc. (Azitra) was established in 2014 to leverage the promise of the microbiome to address both skin disease (e.g. eczema, netherton’s, etc.) and adverse skin conditions (e.g. flaky, dry, rough skin). Skin disease and skin problems afflict millions of individuals worldwide. The Company believes that the microbiome holds the key to addressing these challenges and has assembled an experienced team of drug development specialists, microbiologists, biochemists, dermatologists and experts in industrial microbiology to meet its goals. Azitra has robust technical platform and 3 products entering clinical development in 2019.

  • Date:Monday, February 11
  • Time:10:00 AM - 10:15 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23337
  • Goal for Presentation:Banker development for IPO
  • Company Website:www.azitrainc.com
  • Company HQ City:Farmington
  • Company HQ State:Connecticut
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$5.2
  • Size of Last Investment Round:$2.1
  • Previous and Current Investors:Bios Partners, Breakout Labs, Connecticut Innovations, KdT
  • CEO/Top Company Official:Richard Andrews
  • Year Founded:2014
  • Main Therapeutic Focus:Dermatology
  • Lead Product in Development:AZT-01 for Atopic Dermatitis
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
  • Additional Information/Comments:Azitra, Inc. is a preclinical stage biotechnology company combining the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its consumer and pharmaceutical programs in atopic dermatitis, dysbiosis in rash associated with cancer therapies and treatment of orphan indications (e.g. Netherton's). The Company is now starting its human testing on a personal care product and will be initiating Phase 1/2 IND studies for its eczema and netherton's programs in 2019. Azitra has an extraordinary IP position covering the use of the microbiome in disease treatment and has established full GMP manufacturing and formulation for its products. The company has an excellent SAB and significant group of investors committed to supporting the Company through it's clinical programs coming in 2019.
Speakers
Richard Andrews
Azitra, Inc.
Back